CILOA
Ciloa technology is the only one allowing to produce all types of membrane proteins with their native conformation on exosomes. It allows to load exosomes with cytosolic proteins as well. It thus makes it possible to reach the most difficult families of membrane protein targets, known as “undruggable”, some being the most promising for therapies.Ciloa takes advantage of the natural properties of exosomes; they are natural immuno-stimulators, biocompatible, intercellular membrane messengers, and able to cross all the human body barriers including the blood-brain barrier.
CILOA
Social Links:
Industry:
Legal Medical Therapeutics
Address:
Montpellier, Languedoc-Roussillon, France
Country:
France
Website Url:
http://www.ciloa.fr
Status:
Active
Contact:
+33 (0) 467 143 997
Email Addresses:
[email protected]
Total Funding:
5 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon WordPress Google Universal Analytics Font Awesome Apache
Similar Organizations
Calimmune
Calimmune is a clinical-stage gene therapy company.
Current Employees Featured
Official Site Inspections
http://www.ciloa.fr Semrush global rank: 5.83 M Semrush visits lastest month: 1.43 K
- Host name: redirect.ovh.net
- IP address: 213.186.33.5
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "Ciloa"
Ciloa, Inspired by exosomes
Ciloa is dedicated to the development of new high potential therapies. It was built on more than 15 years of research on bio-drug development technology using exosomes. Ciloa’s technology …See details»
Contact - Ciloa
For information about the company, press relation, business development or investor relations, contact us.See details»
Ciloa - Crunchbase Company Profile & Funding
Ciloa technology is the only one allowing to produce all types of membrane proteins with their native conformation on exosomes. It allows to load exosomes with cytosolic proteins as well. It …See details»
Ciloa | BIO-Europe Spring - Informa Connect
Ciloa is a French preclinical biotechnology company, spin-off from the CNRS and the University of Montpellier, with the world's leading experience in the development of exosome-based …See details»
Ciloa - Eurobiomed
Ciloa maîtrise des cibles de défi pour développer de nouvelles solutions thérapeutiques et préventives. Ciloa agit sur la machinerie cellulaire impliquée dans la production d’exosomes et …See details»
Technology - Ciloa
The membrane proteins of Ciloa (GPCR, ion channels, viral envelope proteins…) are naturally expressed in the cells and sorted in exosome membranes with their fully native conformation. …See details»
Ciloa 2025 Company Profile: Valuation, Funding
Information on valuation, funding, cap tables, investors, and executives for Ciloa. Use the PitchBook Platform to explore the full profile.See details»
Ciloa Secures €5 Million for the Development of Its …
Mar 8, 2022 About Ciloa: www.ciloa.fr Ciloa is a French biotech company, spin-off of the CNRS and the University of Montpellier, pioneer in the development of vaccines and exosome-based vaccines and therapies.See details»
Ciloa - Drug pipelines, Patents, Clinical trials - Synapse
Explore Ciloa with its drug pipeline, therapeutic area, technology platform, 1 news.See details»
Ciloa - VentureRadar
"Ciloa is dedicated to the production of fully native membrane proteins on exosomes. Ciloa exosomes offer a disruptive way to develop a new generation of therapeutic and preventive …See details»
Ciloa rejoint les membres AFSSI - AFSSI Sciences de la …
Apr 29, 2024 Découvrez les sociétés ayant rejoint les rangs AFSSI. Aujourd’hui, plus de 90 sociétés de services et d’innovation en santé, toutes hyper-qualifiées dans leurs domaines et complémentaires à l’échelle de la filière. Bienvenue à …See details»
Ciloa, les traitements thérapeutiques à base d’exosomes
Ciloa, une pionnière en matière de nouvelles thérapies. Basée à Montpellier, la société développe une nouvelle génération de traitements fondés sur les exosomes, vésicules nanoscopiques …See details»
Missions - Ciloa
Ciloa is dedicated to the development of new high-potential therapies through its bio-drug development technology using exosomes. Thanks to its technology, the most advanced in the …See details»
Ciloa SAS at the Swiss Biotech Day
Ciloa, a pioneer in in vivo exosome bioengineering, has stabilized highly multimerized and functional adiponectin by anchoring it on exosomes. Pairing these adiponectin-exosomes with …See details»
Ciloa secures €5 million for the development of its new generation …
Mar 8, 2022 Ciloa is developing its innovative vaccine using its unique and proprietary exosome modification technology platform for the development of a new class of biologics. Exosomes …See details»
Ciloa cible virus et tumeurs avec de nouveaux agents thérapeutiques
La start-up montpelliéraine Ciloa travaille sur un nouvel arsenal thérapeutique destiné au traitement de cancers ou de maladies infectieuses, basé sur les exosomes, sortes de …See details»
Ciloa’s project among the 11 winners of the “Sanofi iTech Awards”
Feb 15, 2021 French biotech company Ciloa wins the 2020 “Sanofi iTech Awards”. The winning project is based on the unique innovation developed by Ciloa, which uses its customized …See details»
Montpellier : un aperçu de la médecine du futur à Ciloa, société ...
Feb 15, 2022 La ministre de la Recherche et de l’Innovation Frédérique Vidal était à Montpellier, ce lundi 14 février.See details»
Antibodies - ciloa.fr
The antigens necessary to develop monoclonal antibodies that recognize conformational epitopes must exhibit fully native conformation. This is particularly challenging for proteins with multi …See details»
Vaccins : La biotech Ciloa crée sa nouvelle unité de production aux ...
Ciloa, société pionnière spécialisée dans la customisation in vivo d’exosomes, annonce la mise en place d’une unité de production conçue pour répondre aux normes GMP (Good …See details»